Technological projects portfolio
PTPS-VAC
Personalized anti-cancer vaccines made from unconventional neoantigens
Investment: €984k
Scope: Healthcare
Scientific field(s): Biology and medicinal chemistry
Institution(s): Université Paris-Saclay - Inserm - Gustave Roussy
Development: Start-up in progress/completed
USE CASES
Cancer treatments by immunotherapy, i.e. mobilizing the patient’s immune system in the fight against the disease, are in full expansion.
Among the new strategies, therapeutic peptide vaccines work by training and stimulating the immune system, by injecting the patient with peptides specific to the tumors present.
However, the results obtained up to now have been disappointing, while many surface peptides of tumors (or epitopes) have never been studied.
ADVANTAGES
While a large number of potentially useful epitopes cannot be identified using current methods, the objective of the PTPS-VAC project is to develop a new, exhaustive identification strategy for neoepitopes, which are new “unconventional” peptides with a high potential for antigen presentation using patient biopsies.
APPLICATIONS
The PTPS-VAC project aims to identify new anti-cancer vaccine candidates, with lung and colon cancer as the first targets. There is also a plan to set up a proteogenomic platform for identifying neoepitopes using patient biopsies, paving the way for personalized treatments.
